APTO Aptose Biosciences Inc.

6.22
+0.18  (+3%)
Previous Close 6.04
Open 6.12
Price To Book 11.09
Market Cap 473,377,703
Shares 76,108,031
Volume 55,060
Short Ratio
Av. Daily Volume 1,353,273
Stock charts supplied by TradingView

NewsSee all news

  1. Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

    SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  2. Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

    SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  3. Aptose Announces Closing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced the closing of its previously announced underwritten public offering

  4. Aptose Announces Pricing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it priced its previously announced underwritten public offering

  5. Aptose Announces Proposed Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it has commenced an underwritten public offering of its common

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data noted favorable safety profile - December 7, 2019.
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Phase 1 data noted safety profile remains clean (two patients) - December 7, 2019.
CG-806
Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)

Latest News

  1. Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

    SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  2. Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

    SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  3. Aptose Announces Closing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced the closing of its previously announced underwritten public offering

  4. Aptose Announces Pricing of Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it priced its previously announced underwritten public offering

  5. Aptose Announces Proposed Public Offering of Common Shares

    SAN DIEGO and TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), today announced that it has commenced an underwritten public offering of its common

  6. Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

    SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying

  7. Aptose Presents Highlights From Corporate Event At ASH

    SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS) released highlights from a corporate event and clinical update today held at the 61st American

  8. Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

    SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of

  9. Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  10. Aptose to Present at BIO-Europe Conference

    SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of

  11. Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

    – Company to Hold Event During ASH –  – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS), a

  12. Aptose Reports Results for the Third Quarter Ended September 30, 2019

    CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call and Webcast at 5pm

  13. Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

    SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the

  14. Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

    SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target